The Native Antigen Company product pipeline reflects our specialism in the manufacture of infectious disease antigens to ensure retention of their native configuration. From initial research through to production scale-up we are focused on providing antigens which deliver real improvements to the sensitivity and specificity of serology based IVD’s, serve as effective immunogens and offer vital support in vaccine research. Our antigens are manufactured using either: (i) culture, isolation and purification or (ii) via our mammalian expression systems. We seek to avoid the use of non-mammalian expression systems such as E. coli which often fail to give sufficient representation of the true native state.
Our current R&D pipeline includes:
- Dengue virus serotype 1 and 3 Envelope proteins
- Oropouche virus antigens
- Dengue virus NS3 and NS5 antigens
- Crimean Congo Haemmorraghic Fever virus antigens
- Lassa Fever virus antigens
- Nipah virus proteins
- MERS recombinant antigens
If any of these antigens are of interest, please get in touch to be included in our beta testing, and to be first to partner using our unique antigens.